Last reviewed · How we verify

lidocaine treatment

Centre Hospitalier Universitaire, Amiens · Phase 3 active Small molecule

Lidocaine blocks sodium channels in nerve cells, preventing the initiation and transmission of nerve impulses.

Lidocaine blocks sodium channels in nerve cells, preventing the initiation and transmission of nerve impulses. Used for Local anesthesia for minor surgical procedures, Treatment of ventricular arrhythmias.

At a glance

Generic namelidocaine treatment
SponsorCentre Hospitalier Universitaire, Amiens
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

This action results in a reduction of the excitability of the nerve membrane, which in turn leads to a decrease in the release of pain-causing chemicals. Lidocaine's mechanism of action is primarily through its ability to bind to and block the sodium channels, preventing the rapid depolarization of the nerve membrane.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: